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ABSTRACT
In the course of studies aimed at the role of oxidative stress in the development of
metastatic potential in the LNCaP-C4-2B prostate cancer progression model system, we
found a relative decrease in the level of expression of the cytoplasmic nicotinamide
riboside : quinone oxidoreductase (NQO2) and an increase in the oxidative stress in C42B cells compared to that in LNCaP or its derivatives C4 and C4-2. It was also found that
C4-2B cells specifically shed large extracellular vesicles (LEVs) suggesting that these
LEVs and their cargo could participate in the establishment of the osseous metastases.
The level of expression of caveolin-1 increased as the system progresses from LNCaP
to C4-2B. Since NQO2 RNA levels were not changed in LNCaP, C4, C4-2 and C4-2B,
we tested an altered cellular distribution hypothesis of NQO2 being compartmentalized in
the membrane fractions of C4-2B cells which are rich in lipid rafts and caveolae. This was
confirmed when the detergent resistant membrane fractions were probed on
immunoblots.

Moreover, when the LEVs were analyzed for membrane associated

caveolin-1 as possible cargo, we noticed that the enzyme NQO2 was also a component
of the cargo along with caveolin-1 as seen in double immunofluorescence studies.
Molecular modeling studies showed that a caveolin-1 accessible site is present in NQO2.
Specific interaction between NQO2 and caveolin-1 was confirmed using deletion
constructs of caveolin-1 fused with glutathione S-Transferase (GST). Interestingly, whole
cell lysate and mitochondrial preparations of LNCaP, C4, C4-2 and C4-2B showed an
increasing expression of glutaminase (GLS, kidney type). The extrusion of LEVs appears
to be a specific property of the bone metastatic C4-2B cells and this process could be
inhibited by a GLS specific inhibitor BPTES, suggesting the critical role of a functioning
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glutamine metabolism. Our results indicate that a high level of expression of caveolin-1
in C4-2B cells contributes to an interaction between caveolin-1 and NQO2 and to their
packaging as cargo in the shed LEVs. These results suggest an important role of
membrane associated oxidoreductases in the establishment of osseous metastases in
prostate cancer.

INTRODUCTION

Prostate adenocarcinoma is recognized as the second leading cause of death in
men in North America (1). Although the mechanisms by which prostate cancer is driven
are not yet completely understood, aspects such as age, race, family history of prostate
cancer, lifestyle, and diet are factors are under investigation (2-4). Prostate cancer
incidence is tested on the basis of the prostate-specific antigen (PSA) blood test and
histological stages (5). Early stages of prostate cancer exhibit cells that are only able to
survive in an androgen-rich environment and hence they are often treated with androgendeprivation therapies. While it is common that bony metastases are seen at first clinical
diagnosis of prostate cancer in many men, there is also an increasing suspicion that the
selective and stringent pressure imposed by the androgen ablation therapy on the
residual prostate cancer cells might actually accelerate the development of more
aggressive, metastatic and rapidly growing prostate cancers (6). This is particularly in part
due to fact that the prostate cancer cells are adept at maintaining functional androgen
receptor signaling even in an androgen-independent environment, to drive cancer growth
and to acquire a metastatic advantage (6,7). Studies have been done to dissect the
mechanisms that drive prostate cancer transition from androgen dependence to androgen
3

independence, in animal models (8,9). However, the complete molecular mechanism of
prostate cancer progression is yet to be elucidated, and therefore, even the best available
treatment for advanced prostate cancers often result in debilitating osseous metastases,
often with a fatal outcome (10,11).
The LNCaP prostate cancer progression model, developed by Leland Chung’s
laboratory, systematically recapitulates the way in which prostate cancer develops and
eventually metastasizes preferentially to the skeleton (12,13). Thus, this model system
lends itself to systematic pre-clinical studies to understand the stages involved in prostate
cancer progression to androgen independence and the establishment of bony
metastases. Characterization of the LNCaP progression model revealed an increasing
“bone cell-like” differentiation from LNCaP human prostate carcinoma cells to its
derivatives C4, C4-2, and C4-2B. Interestingly, LNCaP and C4 are androgen dependent
whereas C4-2 and C4-2B cells are androgen independent. This in vitro model mirrors the
progression of human prostate cancer in vivo (12,13). In addition to being androgen
independent, C4-2B cells have the propensity to metastasize to the bone. Bone is a
restrictive and protective environment that is normally hostile to the growth and survival
of cancer cells metastasizing from another organ. Therefore, in order for prostate cancer
cells to metastasize in the bone, they mimic the properties of osteoblasts and osteoclasts,
types which bone cells are made of, in order to survive, a phenomenon known as
“osteomimicry”.

The classic “seed and soil” theory states that the soil, the bone

microenvironment, determines the selectivity of seed, in this case the prostate cancer
metastatic cell line C4-2B (14,15). Therefore, in order for the seed to take root, the
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prostate cancer cells closely mimic the fertile soil of the local bony microenvironment by
exhibiting osteomimicry.
Several epidemiological studies indicate that while the rate of occurrence of
clinically indolent prostate cancer is similar worldwide, the rate of occurrence of clinically
significant and metastatic prostate cancer is markedly lower in Asia than in Western
populations (16). It has been proposed that these differences could be due, a large part,
to the influencing factors such as diet and other nutritional factors rather than genetic
variations because Asian men who adopt a Western life style show an increasing
incidence of clinically significant disease (17).

Apart from Asian men, incidence of

prostate cancer among men is also significantly low in France which is due, a significant
part, to a large intake of red wine, a natural source of resveratrol, leading to the concept
of “French Paradox” (18,19). Work from our laboratories have focused for many years
on the molecular mechanisms of androgen independence and bone metastasis in
prostate cancer, with particular reference to the use of curcumin (used in Asian cuisine)
and resveratrol (found in red wine) as significant anti-inflammatory, anti-oxidative agents
and as nutritional modulators of cancer progression (20-24). Our earlier work on the
mechanisms of androgen independence in prostate cancer cells has led to a better
understanding of the function of the enzyme NRH: Quinone oxidoreductase (NQO2) in
prostate carcinogenesis (25, 26). In this communication, the role of the enzyme NQO2
is investigated further with respect to its role not only in regulating oxidative stress but
also in regulating prostate cancer metastasis and how glutamine metabolism influences
all these processes. Our results highly suggest a heretofore uninvestigated role for the
enzyme NQO2 in the genesis and function of large extracellular vesicles (LEVs),
5

particularly in the modulation of the bony microenvironment in advanced prostate cancer
through its specific interaction with caveolin-1 which is implicated in the genesis of
hormone refractory and metastatic prostate cancer.

MATERIALS AND METHODS
Cell Culture:
The human prostate cancer cell lines used in this study are LNCaP, C4, C4-2 and
C4-2B. Of these, the LNCaP cell line (as its fast growing version, FGC) was originally
purchased from American Type Culture Collection (ATCC). The sublines C4, C4-2 and
C4-2B derived from the parental LNCaP were originally developed and extensively
characterized by Chung and his laboratory (12,13). These cell lines were procured from
ViroMed Inc and preserved in liquid nitrogen and cultured as described previously (21,
22). The non-cancerous immortalized human prostate epithelial cell line RWPE-1 was
purchased from ATCC and cultured in a medium containing keratinocyte serum free
medium supplemented with bovine pituitary extract and human recombinant epidermal
growth factor (Invitrogen, Inc).
Antibodies and reagents:
Antibodies to NQO2 (monoclonal) was purchased from Origene Technologies, Inc.
Polyclonal antibody to Glutaminase (GLS) was from Novus Biologicals Inc. Antibodies to
NQO1 (monoclonal) and β-actin (polyclonal) and caveolin-1 (polyclonal) were from Santa
Cruz Biotechnologies, Inc. The cell permeable GLS inhibitor BPTES was purchased from
Sigma-Aldrich, Inc.
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Analysis of oxidative stress inherent in un-induced prostate cancer cells:
This was done using the CellROX green oxidative stress assay kit for live cells,
purchased from Thermo Fisher Scientific, Inc. The four prostate cancer cell lines were
plated in chambers in a 4- well chamber-slide format (Lab Tek II chamber slide system,
Nalge- Nunc International). When the cells were around 70% confluent, the cells were
treated with CellROX green reagent at a final concentration of 5µM and incubated at 370C
for 30 minutes. They were then washed thrice with 1X phosphate buffered saline (PBS),
the chambers were removed and the slides were finally mounted using Vecta Shield
antifade mounting medium supplemented with DAPI (Vector Labs, Inc) and cover slips.
The slides were then visualized through a Nikon Eclipse 90i fluorescence microscope and
images were captured at the excitation/emission wavelengths of 485 and 520nm
respectively.
Isolation and Reverse Transcription of RNA:
Isolation of total RNA from all the 4 prostate cancer cells were done through the
TriZol method, following manufacturer’s protocols (Bio Rad, Inc) and quantitation was
done by following its absorbance at 260 nm. The first strand synthesis was done using
the oligo-dT primer and MuMLV-reverse transcriptase (New England BioLabs, Inc) using
the standard protocol supplied by the manufacturer.
Semi-quantitative PCR amplification of NQO1, NQO2 and β-actin transcripts:
The design of the sense and anti-sense primers for the genes NQO1, NQO2 and
β-actin (for expression control) was done exactly as described previously by Strassburg
et al ( 27). NQO1, NQO2 and β-actin genes were amplified separately using the specific
7

primers, under the PCR conditions described by these authors, using the thermostable
TaqMan DNA polymerase (Applied Biosystems, Inc) and Applied Biosystems Gene Amp
PCR system 2400. One tenth of the total PCR product for each was run on a 1% agarose
gel containing 1 μg/ml ethidium bromide and the gel was imaged through the gel
documentation system. Under these conditions, NQO2, NQO1 and β-actin yielded a PCR
product of 623, 366 and 202 bps respectively.
Cell proliferation assays:
RPMI-1640 culture medium supplemented with 2mM or 0.1 mM glutamine were
added to 12 well plates with a final volume of 1ml per well and seeded with LNCaP, C4,
C4-2 and C4-2B cells at day 0 at a density of 1X105 cells per well. Following cell
attachment, growth medium with the same concentration of glutamine was replaced the
next day and subsequently every 2 days. At day 6, the cells were trypsinized, suspended
in 1ml of medium and the cells were counted using a hemacytometer to determine the
total number of cells per well. All cell proliferation assays were done in duplicate.
Immunoblot analysis:
Whole cell lysates were prepared in lysis buffer consisting of 50 mM Tris-HCl buffer
pH 8.0 supplemented with 1% Triton X-100, 150mM NaCl, 2mM sodium orthovanadate,
2mM PMSF, 50mM sodium β-glycerophosphate and HALTTM protease inhibitor cocktail
at 1X concentration. Protein concentrations were determined by using the BCA assay
(Thermo Scientific, Inc). Pre-determined quantities of lysate proteins were denatured with
the complete reducing SDS-sample buffer (Sigma –Aldrich Inc) by boiling for 5 minutes.
The denatured lysates were then resolved on Bio-Rad Criterion gels at either 8% or at
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12% acrylamide concentrations.

The resolved proteins were transferred to PVDF

membranes (Bio-Rad). The membranes were blocked with 5% blotting grade defatted
dry milk (Bio-Rad) in Tris-buffer-saline supplemented with 0.1% Tween-20 for 1 hr at room
temperature. The blocked membranes were probed overnight at 40C in the primary
antibody solution at concentrations recommended by the manufacturer in TBS-Tween
supplemented with 1% dry milk. After washing three times in TBS-Tween, the blots were
probed with the corresponding secondary antibody (at 1:3000 dilution) conjugated with
horse radish peroxidase for 1 hr at 40C. After the final washes, the signal was developed
with the enhanced chemiluminescence reagent Luminol ( Santa Cruz Biotechnology, Inc)
as recommended by the manufacturer and the bands were captured on to HyBlot ES
autoradiography film (Denville Scientific, Inc).
Molecular modeling for NQO1 and NQO2 and identification of potential caveolin-1
binding sites:
This is done following the Pymol molecular modeling program, following specific
instructions from the software for the target proteins NQO2 and NQO1.
Isolation of detergent resistant membranes from prostate cancer cells:
LNCaP, C4, C4-2 and C4-2B cells were cultured as described earlier in 60 mm
plates and grown to 80% confluency. The cells were fractionated into detergent soluble
and detergent resistant fractions as originally described by Hamaguchi and Hanafusa
(28). Briefly, the CSK buffer used consists of 10 mM Pipes pH 6.8, 100 mM KCl, 2.5 mM
MgCl2, 1mM CaCl2, 0.3 M sucrose, 1mM phenylmethylsulfonyl fluoride (PMSF), 1%
Trasylol (Aprotinin), 1mM sodium orthovanadate, 10µM sodium molybdate, 1% Triton X-
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100. Grown cells were washed with Tris-buffered saline and incubated with 0.5 ml of
CSK buffer for 3 min on ice with gentle shaking every 30 sec. The supernatant was
collected and the insoluble matrix structure that remained on the dish was again
incubated for 1 min on ice with an additional 0.5 ml of fresh CSK buffer. The supernatants
from the two incubations were pooled and used as the detergent soluble fraction. The
residual structure remaining on the dish was collected with 0.3 ml of 1X RIPA buffer (
Santa Cruz Biotechnologies, Inc) supplemented with 2mM sodium ortho-vanadate and
1X protease inhibitor cocktail ( Santa Cruz) and used as the detergent resistant fraction.
Both fractions were centrifuged at 15,000g for 30 min and the supernatants were used
for analysis.
Double immunofluorescence for probing caveolin-1 and NQO2:
The four prostate cancer cell lines were cultures on Lab Tek II 4-well chamber
slides as mentioned before. When they are 70% confluent, the slides with the chambers
still intact were washed with serum free medium (RPMI-1640) three times and then
incubated with 1 ml of the same serum free medium overnight at 370C. The chambers
were then washed with 1X PBS and fixed with an acetone:methanol mix (1:1 vol/vol) at 200C for 20 min, the fixed cells were immersed in IX PBS and were processed for double
immunofluorescence as follows. The chambers were treated with 5% donkey serum in
1X PBS supplemented with 0.5% Triton-X100 ( blocking buffer which also permeabilizes
the cells) for 1 hr at room temperature. The chambers were treated with the 1st primary
antibody (polyclonal anti-caveolin-1, Santa Cruz Biotechnologies, Inc) in blocking buffer,
at a dilution of 1:150), in a final volume of 150 microliters overnight at 40C. After this
treatment, the chambers were washed three times with 1X PBS, for 10 min each at room
10

temperature. The chambers were treated with the 1st secondary antibody , ie., Alexa-488
conjugated donkey anti-rabbit IgG (Invitrogen, Inc), diluted in 1X PBS (1:300) for 2 hrs at
room temperature. The chambers were washed in IX PBS as described before and
treated again with blocking buffer for 1hr at room temperature. The chambers were then
treated with the 2nd primary antibody (monoclonal antibody to NQO2, Origene
Technologies) in blocking buffer at a dilution of 1:150, overnight at 40C. The next day,
the chambers were washed with IX PBS and treated with the 2nd secondary antibody
(Alexa 594-conjugated donkey anti-mouse IgG from Invitrogen, diluted in 1XPBS at a
dilution of 1:300). For this secondary antibody treatment, the above diluted solution was
centrifuged at 12000g for 30 min at 40C to remove some fluorochrome crystals that
interfere with the immunofluorescence analysis. The supernatant was used to treat the
chambers for 2 hrs at room temperature. After this final treatment, the chambers were
washed three times with 1X PBS to remove the excess fluorochromes. The chambers
were now removed and the slide was mounted with VectaShield antifade (with DAPI)
mounting medium (Vector Labs Inc) and sealed with a cover slip.

The

immunofluorescence of the two fluorochromes were captured using the Nikon
fluorescence microscope as described earlier.
GST-caveolin-1 (wt and deletion mutants) pull down assay:
The full length caveolin-1 (cav-1, amino acids 1-178) and its deletion mutants
(amino acids1-101 and amino acids 82-101) were fused with Glutathione S-Transferase
(GST). Along with a GST only negative control, all the GST-constructs were a kind gift
from the laboratories of D. Volonte and F. Galbiati of the University of Pittsburgh School
of Medicine. All these constructs were transformed into E Coli BL-21 strain and selected
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for ampicillin resistance. Logarithmically growing cells were induced for recombinant
protein expression through the addition of 5mM isopropyl thiogalactopyranoside (IPTG,
Sigma-Aldrich). All the GST-cav-1 constructs were affinity purified by passing through
glutathione (GSH)-agarose beads using the detergent sarcosyl for initial solubilization.
Purified GST alone ( negative control), GST-cav-1 (full length 1-178), GST-cav-1 mutant
( 1-101), GST-cav-1 mutant (82-101) proteins were immobilized on to GSH agarose
beads and washed three times with TNET buffer ( 50 mM Tris HCl pH 8.0, 150 mM NaCl,
5 mM EDTA and 1% Triton-X100 containing 1X HaltTM protease ( Pierce Biotechnology,
Inc) inhibitors.

Whole cell extracts [prepared using radioimmunoprecipitation assay

buffer, (RIPA) from Santa Cruz, Inc] from logarithmically growing LNCaP cells were
treated with each of these GSH-agarose immobilized proteins in a batch format overnight
at 40C in TNET buffer. The unbound proteins were removed by brief centrifugation and
the beads were washed three times with the same TNET buffer. The bound proteins
were eluted and denatured with 2X SDS-PAGE denaturing buffer and subjected to gel
electrophoresis under denaturing conditions. The resolved proteins were transferred to
PVDF membranes as described above and probed with anti-NQO2 antibody (monoclonal,
Origene Technologies Inc).
Isolation of large extracellular vesicles (LEVs):
Large extracellular vesicles were purified by differential centrifugation from the
conditioned medium prepared from the prostate cancer cell lines as well as the
immortalized non-tumorigenic primary epithelial prostate cell line RWPE-1. For each cell
line, two confluent 150 mm dishes were used (nearly 30 million cells). The cells were
washed three times with sterile phosphate buffered saline (1X PBS) and incubated further
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in serum free RPMI-1640 medium for 12 more hours. The conditioned medium (CM) from
these serum starved conditions was removed from the cells and centrifuged at 300g for
10 minutes to pellet intact cells, which were discarded. The supernatant from this
centrifugation was centrifuged at 1000g for 10 minutes to pellet cell debris.

The

supernatant from this centrifugation was filtered through a 0.22μm steri-flip filter unit
(Millipore) with a PVDF membrane. The large extracellular vesicles retained by the filter
was washed once with 1X PBS and re-suspended in 0.5 ml of the same buffer.
Alternatively, the supernatant obtained after the 1000g centrifugation was processed
again for ultracentrifugation in a SW 50.1 rotor in a Beckman Ultracentrifuge at 100,000g
for 60 minutes. This ultracentrifugation step yielded a pellet which consisted of both LEVs
and smaller sized EVs. For treatment of cells with a specific Glutaminase (GLS) inhibitor
(BPTES), the respective cells grown in 60 mm dishes in rich medium to 70% confluency
was treated with BPTES at a final concentration of 10 µM for 24 hours. At the end of this
period, the cells were washed in 1X PBS and cultured in serum free medium in the
presence of 10µM BPTES for a further period of 12 hours. Subsequent harvesting of
LEVs from the BPTES treated conditioned medium was done through membrane filtration
as described above.

RESULTS:
Differential expression of NQO2 in the prostate cancer progression model system:
The relative levels of expression of the enzyme NQO2 and caveolin-1 were
followed using the whole cell extracts of LNCaP, C4, C4-2 and C4-2B cells. As negative

13

and loading controls, the expression levels of the enzyme NQO1 as well as β-actin were
also followed on the same gels by re-probing the blots. The results are shown in Figure
1A. It is evident that while caveolin-1 expression progressively increased, the level of
NQO2 changed in a biphasic manner, first increasing from LNCaP to C4, peaking at C42 followed by a precipitous decrease at the C4-2B stage. These results, at the minimum,
suggest that NQO2 is being unexpectedly reduced compared to caveolin-1 in C4-2B cells.
To obtain additional information on the discordant changes in NQO2 and caveolin-1 with
respect to prostate cancer progression and metastasis, total RNA was prepared from
these cells and mRNA expression corresponding to NQO1, NQO2 and β-actin was
assayed by RT-PCR. In contrast to the immunoblots data shown in Figure 1A, relatively
constant levels of mRNA expressions of NQO2 as well as NQO1 were observed (Figure
1B). These PCR results suggest that the relatively lower level of expression of NQO2 in
the bone metastatic C4-2B cell line is not likely mediated by a transcriptional mechanism
but could be attributed to a post-translational event that effectively lowers the intracellular
concentration of this enzyme.
The C4-2B metastatic progression is accompanied by an increase in levels of
oxidative stress:
Since NQO2 participates in the detoxification of reactive oxygen species including
intracellular semiquinones, its decreased expression during LNCaP progression to C42B could result in cell stage-dependent change in intracellular oxidative stress. This
possibility was tested using the CellROX Green oxidative stress assay kit (InVitrogen,
Inc). The assay involved a cell permeable fluorogenic probe which displays a weakly
fluorescent signal in the reduced state and exhibits a bright green photo-stable
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fluorescence upon oxidation by intracellular reactive oxygen species (ROS) allowing it to
bind to DNA with an absorption/emission maximum of 485/520 nm.

Thus, the

fluorescence intensity of this probe is an indirect measurement of the intracellular ROS
levels. Results in Figure 1C show a progressive increase in the ROS levels from LNCaP
to C4-2B similar to what has been demonstrated in several cancer cell systems (29,30).
A sub fraction of NQO2 is associated with detergent resistant membranes of
prostate cancer cells:
Although the reduced expression of NQO2 could account for the increased
intracellular ROS during LNCaP progression to the metastatic stage, the mechanisms
that might underlie the lowered level of NQO2 remain to be determined. We hypothesized
that NQO2 while largely cytoplasmic acting as a ROS detoxification enzyme may acquire
a novel structural and functional role by becoming compartmentalized in membranes. To
investigate this hypothesis, we prepared detergent soluble and detergent resistant
fractions of LNCaP, C4, C4-2 and C4-2B cells using established protocols and probed for
NQO2 expression by immunoblot analysis.

Interestingly, we found a significant

localization of NQO2 in the detergent insoluble membrane fraction and that the relative
proportion of membrane associated NQO2 increased as cells progressed from LNCaP to
C4-2B (Figure 2A). For loading controls, equivalent amount of estimated protein was
loaded for lanes 1 and 2 in this Figure. For the detergent resistant membrane fraction
which is devoid of most protein, one-tenth of the extracted membrane fraction was loaded
in this study (lane 3). Since C4-2B cells show the most phenotypic changes such as
increased oxidative stress, increased caveolin-1 expression and decreased NQO2
expression, we wished to characterize the detergent resistant membrane fractions from
15

this cell line further, the results of which are shown in Figure 2B. As expected, the β-actin
levels are equivalent in the whole cell lysate (lane 1) and the detergent soluble (lane 2)
fractions and there was a significant reduction in its expression in the detergent resistant
(lane 3) membrane fraction. Other membrane markers such as Flotillin-1 and caveolin-1
showed higher expressions in the detergent resistant membrane fraction. Interestingly,
the cytoplasmic marker oncogene p60c-src did not localize with the detergent resistant
membrane fraction which served as a negative control (28). These results suggest that
there is a compartmentalization of NQO2 in detergent resistant, caveolae rich membrane
fractions of C4-2B cells.
Molecular modeling reveals potential caveolin-1 binding sites in NQO1 and NQO2:
Since the detergent resistant fractions isolated are known to be rich in lipid rafts
and caveolae, we further hypothesized that NQO2 may be associated with the caveolae
and specifically with caveolin-1. To determine whether caveolin-1 binding sites are
intrinsically present in the NQO2 protein, we performed molecular modeling of NQO2.
For comparison, the sites potentially available on a related quinone oxidoreductase
NQO1 was also analyzed as a negative control. Analysis of the NQO2 and NQO1 protein
sequences using the PyMol modeling software revealed that there are two caveolin-1
consensus binding sites in NQO2 and one such binding site in NQO1. Interestingly, we
found that all caveolin-1 binding domains (CBD) are directed towards the scaffolding
domain of caveolin-1 (CSD) which mediates direct protein-protein interactions between
caveolin-1 and a variety of signaling molecules. These signaling molecules possess the
CBD consensus sequence ΦXΦXXXXΦ, ΦXXXXΦXXΦ, ΦXΦXXXXΦXXΦ, where Φ
represents an aromatic amino acid and X represents any amino acid (31, 32). Thus,
16

NQO2 has two putative CBD between amino acids 149 and 157 and between 175 and
182 while the sequence of NQO1 between amino acids 100 and 107 of NQO1 also
conforms to the consensus CBD. However, the sequences in NQO2 (149-157) and in
NQO1 (100-107) are buried in the core of the protein, near the isoalloxazine ring of the
flavin binding site and hence, not likely to be available for binding to caveolin-1. By
contrast, the sequence in NQO2 (175-182) is located at the periphery and spatially
available for potential protein-protein interactions with caveolin-1 (Figure 2C).
Glutathione-S-Transferase-fused caveolin-1 construct pull-down assays confirm
that NQO2 interacts with caveolin-1:
To investigate whether caveolin-1 is a binding partner for NQO2, we performed
pull-down assays using a series of caveolin-1 deletion constructs fused with glutathioneS-transferase (GST) and non-denaturing whole cell lysates from LNCaP prostate cancer
cells. Figure 3 shows that NQO2 is a bona fide caveolin-1 binding protein and that at the
minimum, the scaffolding domain of caveolin-1 (amino acids 82-101, fused to GST) was
sufficient for binding to NQO2. Many other investigators have found that this scaffolding
domain of caveolin-1 also interacts with several significant signal modifiers such as βcatenin, thioredoxin reductase-1, Nrf2 etc, to keep them in an inhibited state, thus
regulating signal flow.
Both caveolin-1 and NQO2 are specific components of the cargo carried by the
large extracellular vesicles (LEVs) of bone metastatic C4-2B cells:
Currently, there is a large body of evidence showing that cancer cells interact and
communicate with normal and healthy cells such as fibroblasts present in the tumor
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microenvironment (TME). Cancer cells accomplish this mainly by their ability to release
extracellular vesicles that appear to play the role of molecular trojan horses in that they
carry important signaling proteins and other cargo to be transferred to neighboring cells
in order to transform them. While the release of smaller exosomes (<100 nm) appear to
be common to both normal cells and cancer cells, the release of large extracellular
vesicles (LEVs) or large “oncosomes” ( >10 µM in diameter) appear to be specific to
cancer cells (33-35). In particular, prostate cancer cells are known to typically release
LEVs which allow them to carry critically significant signaling proteins and other cargo
such as microRNAs etc across tissue barriers (36). Recent work of Di Vizio et al showed
that these LEV release from prostate cancer cells into the blood appear to correlate with
advanced metastatic disease and caveolin-1 was identified as the serum LEV biomarker
(37). Therefore, these observations prompted us to explore the possibility of the release
of these LEVs in the well characterized prostate cancer progression model system of
LNCaP and C4-2B. Since it is already known that caveolin-1 is an integral component of
these LEVs, we hypothesized that NQO2 could also be a cargo carried by these LEVs to
modulate the oxidative stress of the neighboring cells. Our studies indicate that the
release of LEVs is greatly increased in the C4-2B cells as opposed to the parental LNCaP
cells and that the extrusion of both caveolin-1 and NQO2 could be visualized in the LEVs
as shown by double immunofluorescence studies (Figure 4A). As a negative control, we
also looked for the disposition of the related oxidoreductase NQO1 and found that it was
not released in the LEVs from C4-2B cells (Figure 4B).
The C4-2B cells are glutamine addicted as compared to LNCaP, C4 and C4-2:
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We performed cell proliferation studies in rich as well as glutamine deficient
medium after seeding a constant number of cells in 6-well plates. Compared to LNCaP,
C4 and C4-2 cells, C4-2B showed a 60% reduction in proliferation when grown in
glutamine deficient medium. Similar results were obtained when C4-2B cells were grown
in rich medium in the presence of 10 µM BPTES, the specific inhibitor of GLS (Figure not
shown). Our results suggest that these C4-2B cells are critically dependent on the
presence of glutamine for their metabolism, survival and proliferation, compared to its
parental derivatives.
The formation and extrusion of LEVs from C4-2B cells are critically dependent
upon glutamine metabolism, particularly Glutaminase (GLS activity):
Interestingly, we also found that the release of these LEVs is critically dependent
upon the presence of glutamine and its metabolism, particularly the pathway mediated by
the kidney type Glutaminase (GLS). Figure 5A shows a significant reduction in LEV
production from the highly bone metastatic C4-2B cells when the enzyme GLS was
specifically inhibited by the compound BPTES.

Further supporting our observation,

studies from other laboratories indicate that proteins enriched and exported in LEVs
included enzymes involved in glucose and glutamine metabolism. Recent results of
Minciacchi et al show that the glutamine metabolism was altered in cancer cells exposed
to LEVs. These authors showed in their DU-145 metastatic prostate cancer system, the
GLS enzyme was highly and uniquely expressed in the LEV cargo fraction (38). This
prompted us to investigate whether GLS enzyme was also present in the LEVs identified
in the C4-2B bone metastatic system. Figure 5B shows that the GLS extrusion in the
LEVs budding from C4-2B cells (which is not seen in the parental LNCaP, C4 and C4-2
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cells, Figure not shown) as visualized by immunofluorescence. This GLS extrusion in the
LEVs from C4-2B cells could be completely inhibited by BPTES as seen in Figure 5B.
Parallel immunoblot analyses confirm the immunofluorescence pattern of C4-2B
cells:
To gain further supporting evidence for the presence of NQO2, caveolin-1 and GLS
in these LEVs, we also performed immunoblot analyses on the isolated LEVs from
different stages of prostate cancer, as exemplified by the LNCaP progression model
system. Figure 6A shows the results of immunoblots when the whole cell lysates (WCE)
and the large extracellular vesicles (LEV) fractions were run on the same blot and probed
with the respective antibodies such as NQO1, RhoC, β-actin and Glutaminase (GLS). Of
these, the first two proteins served as negative controls. NQO1 is only seen in the WCE
fraction and not in the LEV fraction, a pattern also seen in the immunofluorescence
studies (Figure 4B). The RhoC protein is exclusively cytoplasmic and hence not seen in
the LEV fraction. A small pool of β-actin protein could be seen in the LEV fraction which
is an indication that the LEV blebbing and release in the C4-2B system is critically
dependent on the cytoskeletal organization just below the plasma membrane and that a
fraction of the actin filament proteins such as β-actin is also extruded in these LEVs. This
phenomenon is not seen when parallel studies were done on exosomes as opposed to
LEVs (data not shown). β-actin shedding in LEVs could also be seen in the breast cancer
system as reported independently by another study (39). Thus, β-actin shedding in
several cancer systems appears to be specific to LEVs. Coincidentally, the extrusion of
β-actin could be inhibited to a large extent by the GLS specific inhibitor BPTES. We also
confirmed the presence of the enzyme GLS in these LEVs from C4-2B cells, the extrusion
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of which is again dependent upon glutamine metabolism, particularly GLS activity, as
evidenced by the inhibition of its own shedding by the GLS specific inhibitor BPTES.
These observations give a new meaning for the self-serving nature of glutamine addiction
in cancers. In Figure 6B, we further characterize the extrusion of vesicle specific proteins
such as Flotillin-1 and the cancer specific proteins under investigation in this study, such
as NQO2 and caveolin-1. Flotillin-1 expression, as a marker for the LEV fraction, could
be seen in the LEVs of C4-2B cells in the absence of BPTES and this expression is greatly
reduced in the presence of BPTES. The presence of the proteins that are the focus of this
study, namely NQO2 and caveolin-1 could be seen in the LEV fraction of C4-2B cells in
the absence of BPTES while their expression is greatly reduced in the presence of BPTES
at the concentration used, a pattern that was consistently seen in the double
immunofluorescence studies.
The osteomimicry of the C4-2B prostate cancer cells is dependent upon glutamine
metabolism:
Finally, since we had characterized the link between glutamine metabolism and
the extrusion of LEVs in the highly bone metastatic C4-2B prostate cancer cell line, we
wished to find out whether the well established osteomimicry properties of these cells
could also be influenced by the inhibition of GLS by BPTES. Figure 6C shows the
immunoblot analysis of the osteomimetic marker proteins that are known to be expressed
by the C4-2B cells. Specifically, we followed the expression of bone sialoprotein (BSP,
an osteoblastic marker), receptor activator for NF-kB (RANK, an osteoclastic marker) and
parathyroid hormone related protein (PTHrP, another osteoclastic marker) against the
background expression of the β-actin proteins in the C4-2B whole cell extracts in the
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absence (-) and in the presence (+) of 10μM BPTES. This Figure shows a remarkable
reduction in the level of expression of these osteomimetic marker proteins when these
cells are cultured in the presence of BPTES. These results reveal that the glutamine
metabolism (as shown through GLS inhibition by BPTES) is critically required for both
LEV production as well as the exhibition of osteomimetic properties by these prostate
cancer cells. Since the establishment of osseous metastases by these cancer cells are
critically dependent upon glutamine metabolism, we propose that a specific inhibition of
GLS mediated metabolism and the glutamine addiction of these C4-2B cells could be
therapeutic and could lead to an inhibition of bone metastases.

DISCUSSION:
This study reports the first observation that the enzyme NQO2, largely regarded
so far as a Phase II detoxification enzyme present in the cytoplasm of the cells, has a
membrane component with its membrane associated function. Its localization in the
caveolae and its specific interaction with caveolin-1 suggests that it is specifically
regulated by caveolin-1, similar to the way caveolin-1 suppresses the oncogenic signaling
molecules such as src, Akt, Nrf2, thioredoxin-1, β-catenin etc (40-42). The concept of
duality in caveolin-1 function, both as a tumor suppressor as well as a tumor promoter in
a context dependent way, is well known (43-45). But, our observation that caveolin-1 and
NQO2 form part of the cargo in the large extracellular vesicles suggests that once
caveolin-1/NQO2 is out of their native caveolar compartment, it may lose its potential
tumor suppressor activities and acquire tumor promoting (gain of function) activities when
one considers the dual nature of these proteins (43-45). Specifically, our observations
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highly suggest that the extra-caveolar localization of caveolin-1 and NQO2 may in fact
have a gain of function, possibly in modifying the tumor microenvironment and in
preparing the pre-metastatic niche for the establishment of the metastatic lesion
(according to the seed and soil hypothesis) particularly enhancing the propensity to
establish bone metastases by the C4-2B prostate cancer cells. These capacities are just
the opposite of their tumor suppressive (in the case of caveolin-1) and the ROS and
quinone detoxifying (in the case of NQO2) functions (46, 47). However, these hypotheses
need to be further investigated. Since NQO2 is known to have a dual role as a reactive
oxygen species (ROS) detoxifier as well as a ROS generator, it is possible that this
enzyme may function, in a context dependent way, as a tumor promoter, similar to
caveolin-1 (48,49). Therefore, any strategy to inhibit the formation of these LEVs in
addition to the naturally available anti-NQO2 strategies would be clinically therapeutic and
it would inhibit the formation of bone metastases in advanced prostate cancer patients.
Our studies highlight the obligatory requirement of enhanced glutamine metabolism in the
display of several osteomimetic properties of C4-2B prostate cancer cells as well as the
production of LEVs by these cells. It is possible now to envision how we can interfere
with the establishment of organ specific metastases.

Since the cancer cells from

advanced prostate cancer patients as well as defined cell lines such as C4-2B display
enhanced growth factor receptor expression and activation; activate their proinflammatory NF-kB pathways, express both osteoblast as well as osteoclast specific
proteins, express prostate specific antigen, endothelin-1, Cbfa1 transcription factors etc,
these cells have more in common with the bone microenvironment when compared with
that of the liver or lung (12,13, 21, 22 ). Thus, exhibition of osteomimetic properties and
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the reliance on enhanced glutamine metabolism for the exhibition of these properties are
significant and amenable to therapeutic targeting in a combinatorial manner. One aspect
that is not addressed in our studies is the enhanced synthesis of lipids that is necessary
to form the membranes of LEVs extruded from C4-2B prostate cancer cells. Since these
advanced prostate cancer cells (as well as breast cancer cells and other cancer systems)
show a propensity to increase their lipid synthesis, giving rise to the established concept
of the “lipogenic” phenotype, our studies on the release of LEVs from C4-2B cells
correlate with such enhanced lipid synthesis requirement. Thus, inclusion of a specific
fatty acid synthase (FASN) inhibitor as an adjuvant could be therapeutically beneficial
(50,51).
Our studies suggest that metastasis and glutamine metabolism could be closely
related and regulated in prostate cancer cells and more specifically, in the bone
metastatic prostate cancer cells to achieve their invasive goals. Several other published
studies directly or indirectly support this relationship (52-57). Therefore, anti- GLS therapy
with the use of specific GLS inhibitors (which are currently under clinical trials) should be
considered as therapies to inhibit the formation of bone metastases in advanced prostate
cancer patients as it is likely to break the vicious cycle of bone destruction and bone
formation (21,22,58). At the least, they should be considered as adjuvant therapies along
with the mainstay therapies for late stage prostate cancer patients exhibiting osseous
metastases such as the use of nitrogen containing bisphosphonates (NBPs).
Furthermore, our studies emphasize the importance of the interaction between
caveolin-1 and NQO2. NQO2 joins other bona fide interactors for caveolin-1 such as
Nrf2, Akt, c-src, eNOS, Thioredoxin reductase etc. One common denominator among all
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these interactions is that caveolin-1 keeps all these signaling proteins under check by
suppressing their activities which is facilitated by cavin-1. Studies by several investigators
indicate that caveolin-1 expression was induced without the presence of cavin-1 in
advanced prostate carcinoma and in this context enhanced caveolin-1 expression
activated Akt signaling in prostate cancer, emphasizing again the duality of the function
of caveolin-1 (59-61). Our future studies will investigate the role played by cavin-1 in the
extrusion of these LEVs. NQO2 fits well into the paradigm of LEV cargo containing noncaveolar caveolin-1 influencing the stromal compartment. Yet, more studies are needed
to test this hypothesis. Studies from other laboratories highly suggest that these LEVs
bypass the extracellular and tissue barriers to fuse with the target non-cancerous cell
types (in the stromal compartment) and influence their metabolic and signaling pathways
(62, 63).
Our studies are also important from a translational point of view. For example,
there are several reports that suggest a role of a sudden oxidative burst in otherwise silent
micrometastases that allow them to “wake up” from tumor dormancy. Based on the
studies presented here and considering the fact that NQO2 can produce reactive oxygen
species (ROS) under special circumstances, it is tempting to speculate that such events
may be the “trigger” or a wake-up mechanism for prostate cancer micrometastases, a
mechanism which could well be used by other cancers such as breast cancer (64, 65).
Other than its potential role in tumor dormancy, these results also suggest that the
expression and cellular partitioning of NQO2 and caveolin-1 in LEVs could participate in
the membrane lipid peroxidation induced oxidative stress and membrane reorganization.
A correlation may therefore exist between membrane associated oxidoreductases,
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increased oxidative stress and metastatic potential. Thus, the dual nature of NQO2
function, located mainly in the cytoplasm while at the same time a significant fraction of
which is associated with caveolin-1 at the membrane may underscore the important role
of this enzyme in the establishment of bone metastases.
The interaction between caveolin-1 and NQO2 might also be useful in the research
on melatonin.

It is well known that melatonin is an established inhibitor of cancer

metastasis, although the relevant mechanisms are not yet clear. Since NQO2 has a
melatonin binding site, it would be very interesting to find out how melatonin binding
influences caveolin-1 binding and vice versa and the associated consequences (66, 67).
These studies may have relevance in the inhibition of cancer metastasis in general.
While there is an established relationship between metabolism and metastasis, the
role of cancer cell metabolism in the establishment of organ specific metastasis such as
bone is more specialized than what we have envisioned. For example, if the cancer cells
(bone metastatic prostate cancer cells) exhibit osteotrophic factors such as
Cbfa1/RUNX2, PTHrP1, osteocalcin, osteoprotegerin (OPG) etc, their reprogrammed
glutamine metabolism will facilitate the establishment of osseous metastases. If the
cancer cells express certain hepatotrophic factors, their glutamine addicted metabolism
will help in the establishment of liver metastases. The same concept might be true for
other cancer systems such as breast cancer. Therefore, reprogramming the glutamine
metabolism of these cancer cells might be the least common denominator among the
establishment of all these metastases. Hence, breaking this fundamental glutamine
addiction may well impede the establishment of organ specific metastases for several
cancer systems. Since reprogrammed glutamine metabolism has been shown to be
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important for the formation of large extracellular vesicles (LEVs, as more lipid synthesis
is needed) and since these LEVs are known to interact with the tumor microenvironment
(TME) and possibly facilitate the formation of the pre-metastatic niche etc, it is reasonable
to hypothesize that inhibition of glutamine addiction may well prevent the formation of
organ specific metastases. Figure 7 summarizes all the information that is gleaned from
this study, integrating the conventional (as a Phase II detoxifying enzyme) as well as the
non-conventional role of NQO2 (as a stabilizer of the tumor suppressive protein p53) (68,
69), its possible role on the membrane, its release in LEVs and the possibility of these
NQO2/caveolin-1 containing LEVs in the modulation of tumor microenvironment.
Our results lend further support for the previously published results on the role of
caveolin-1 expression in prostatic hyperplasia, prostatic intraepithelial neoplasia (PIN)
and prostatic adenocarcinoma. Overexpression of caveolin-1 and extracellular caveolin1 have been linked to androgen independence in prostate cancer. In fact, suppression
of caveolin-1 expression induces androgen sensitivity in hormone refractory and
metastatic prostate cancer cells in a mouse model system. In further support, caveolin-1
is also known to regulate hormonal independence through lipid synthesis and abnormal
signaling of the androgen receptor (70-73). The secretion of LEVs and their cargo content
are topics of intense investigation in several cancer systems. Our finding that the
oxidoreductase enzyme NQO2 piggybacking on caveolin-1 and released extracellularly
in LEVs adds a potentially therapeutic significance for the overall role for oxidoreductases
in the modulation of the tumor microenvironment (TME) and in the establishment and
maintenance of bone metastases in prostate cancer. It is also possible that these LEVs
(and their cargo capable of modulating redox systems as shown in our studies) can further
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contribute to the modulation of metabolism in adjacent cancer cells and stromal cells in
close vicinity (74). Quite possibly, a similar phenomenon may function in other solid tumor
systems also. Further studies are needed to explore these interesting possibilities. Our
results give a molecular explanation for the significance of overexpression of caveolin-1
and its externalization with regards to how it may influence hormone refractoriness and
bone metastasis in a metastatic progression model system. This behavior is greatly aided
by an enhanced dependence on glutamine metabolism, which facilitates enhanced lipid
synthesis (needed for the formation of LEVs) through glutaminase (GLS), glutamate
dehydrogenase(GDH), reductive carboxylation of α-ketoglutarate (α-KG) through
isocitrate dehydrogenase (IDH), citrate lyase and finally fatty acid synthase (FASN) as
shown in Figure 7. This paradigm integrates the role of enhanced glutamine metabolism,
enhanced lipid synthesis and lipid metabolism in the establishment of organ specific
metastases (75-78).
Finally, our results suggest a glutamine/GLS mediated metabolic reprogramming
in the LNCaP model system as it progresses toward C4-2B is an integral component of
the force driving the metastatic process. Based on the results of our studies, a
combinatorial strategy using anti-metastatic therapies such as nitrogen containing
bisphosphonates (NBPs) and anti-Glutaminase therapy, or alternatively, a cocktail
consisting of naturally occurring plant compound based anti-NQO2, anti-GLS and antiFASN drugs could be considered for treating advanced prostate cancer patients with
bone metastatic complications. We would like to suggest that the release of caveolin-1,
GLS and NQO2 etc in these LEVs could make them an ideal diagnostic and prognostic
marker (in the serum) for advanced prostate cancer patients. LEVs in these cancer
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systems are known to pack a multitude of other oncogenic proteins, regulatory
microRNAs etc. Thus, the extrusion of a specific protein such as GLS or NQO2 may be
indicative of the severity of the disease.
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FIGURE LEGENDS:
Figure 1A:
Relative levels of expression of NQO2, NQO1, caveolin-1 and β-actin in the LNCaP
prostate cancer progression model system. Characteristically, the level of expression of
NQO2 is decreased in C4-2B cells when the whole cell extracts were analyzed. Whereas,
the expression levels of caveolin-1 showed a progressive increase in this model system.
This apparent inverse relationship between these two proteins formed the basis of our
further investigations.

As a negative control, the expression levels of a related

oxidoreductase NQO1 showed no changes in this progression model system.
Figure 1B:
RNA expression pattern for NQO2, NQO1 and β-actin in the LNCaP prostate cancer
progression model system. The specific primers designed generated a band of 623 bp (
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base pairs) for NQO2; 366bp for NQO1 and 202 bp for β-actin. See Materials and
Methods for the design of the primers and experimental details
Figure 1C:
Oxidative stress analysis in the LNCaP prostate cancer progression model system, using
the CellROX oxidative stress analysis kit. This figure shows significantly increased levels
of oxidative stress in C4-2B cells as opposed to the parental LNCaP cells.
Figure 2A:
A subpopulation of NQO2 is associated with the detergent resistant membrane fraction
of prostate cancer cells. Immunoblot probed with NQO2 antibody. 1: Total lysate; 2:
Detergent soluble membrane fraction; 3: Detergent resistant membrane fraction.
Figure 2B:
Further characterization of the whole cell lysate, detergent soluble and detergent resistant
fractions from the bone metastatic C4-2B cell line with respect to membrane markers
Flotillin-1, caveolin-1. As negative controls, the markers such as β-actin and p60c-src
were also included. Lane 1: whole cell lysate; Lane 2: detergent soluble membrane
fraction; Lane 3: detergent resistant membrane fraction. See text for further details.
Figure 2C:
The potential caveolin-1 binding domains in NQO2 and NQO1 as revealed by PyMol
modeling analysis. The caveolin-1 binding domains are indicated in red and blue. The
externally located caveolin-1 binding domain in NQO2 is depicted in blue. See text for
details.
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Figure 3:
GST-pulldown assay: The recombinant proteins from deletion constructs of Caveolin-1
fused to Glutathione-S-Transferase (GST) were prepared from the respective bacterial
clones and used to pull down the interacting proteins from the lysates of LNCaP prostate
cancer cells. The eluted proteins were then run on a denaturing protein gel and probed
with the NQO2 antibody as described earlier. The use of the recombinant deletion mutant
proteins of caveolin-1 allows for the study of the minimum sequence/structural
requirement of caveolin-1 (ie., the sequence between amino acids 82 and 101, also called
the caveolin scaffolding domain, CSD) that is required to interact with a partner, ie.,
NQO2.
Figure 4A:
Release of large extracellular vesicles (LEVs) from C4-2B cells. LNCaP, C4, C4-2 and
C4-2B cells were grown on 4 well chamber slides, Semi-confluent cells were then fixed
in methanol:acetic acid mixture and processed for double immunofluorescence after
blocking the slides with 5% normal donkey serum in 1XPBS and 0.5% TritonX-100. A
Caveolin-1 rabbit polyclonal antibody (Santa Cruz Biotechnologies, Inc)) and a
monoclonal antibody against NQO2 (Origene Technologies, Inc) were used, each at
1:150 dilution. InVitrogen’s AlexaFluor-488 conjugated to donkey anti-rabbit IgG was
used to bind to the caveolin-1 primary antibody and AlexaFluor-594 conjugated to donkey
anti-mouse antibody was used to bind the NQO2 primary antibody. Processing and
washing and final mounting were done according to manufacturer’s protocol (Vector Labs,
Inc). The final mounting medium (Vector Labs, Inc) also contained the dye DAPI, specific
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for nuclear staining. The large extracellular vesicles that are shedding out of C4-2B
cancer cells can be seen (white arrows).
Figure 4B:
As a negative control to the immunofluorescence studies done for Figure 4A, single
immunofluorescence studies were done on the same cells grown in chamber slides using
a monoclonal antibody for the oxidoreductase NQO1, using a secondary antibody
conjugated to AlexaFluor-594, as shown for Figure 4A.
Figure 5A:
Glutaminase dependency of LEV production from C4-2B cells. Cells were grown in
chamber slides in the absence (A) and in the presence of the cell permeable glutaminase
(GLS) inhibitor BPTES at a final concentration of 10 µM. The shed LEVs in this Figure
are denoted by white arrows.
Figure 5B:
Presence of the Glutaminase enzyme (GLS) in the LEVs arising from C4-2B, in the
absence of BPTES (A) and in the presence of 10μM BPTES (B). A polyclonal antibody
for GLS was used in these immunofluorescence studies along with the AlexaFluor 488
conjugated secondary antibody as described earlier. The GLS in LEVs can be seen (white
arrows)
Figure 6A:
Immunoblot analysis of biomarker proteins that are packaged in the LEVs that arise from
the RWPE-1, LNCaP, C4, C4-2 and C4-2B cells. WCE: Whole cell lysate; LEV: large
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extracellular vesicles. In (A), expression levels of the oxidoreductase NQO1, the
cytoplasmic RhoC, β-actin and Glutaminase (GLS) were followed in the absence (-) and
in the presence of 10 μM BPTES.
Figure 6B:
The expression levels of the LEV marker Flotillin-1, the enzyme NQO2 and Caveolin-1
were followed both in the absence (-) and in the presence (+) of 10 µM BPTES.
Figure 6C:
C4-2B cells show decreased osteomimetic properties when grown in medium
supplemented with the glutaminase (GLS) inhibitor BPTES (10μM). In this immunoblot
the expression levels bone sialoprotein (BSP, an osteoblastic marker), RANK (receptor
activator for NF-kB, an osteoclastic marker), parathyroid hormone related protein ( PTHrP,
an osteoclastic marker) were followed against a backdrop of the expression levels of βactin as loading control.
Figure 7:
A diagrammatic sketch of the impact of reprogrammed glutamine metabolism in
regulating the formation of bone metastases in prostate adenocarcinoma. The duality of
the function of NQO2 as a generator of oxidative stress as well as a stabilizer of p53 ( in
a non-enzymatic fashion) is also depicted. The balance between these two processes,
along with the extent to which the tumor is addicted to glutamine and the level of fatty
acid synthase (FASN) activity may ultimately determine the cancer cell’s propensity to
establish organ specific metastasis. Several other strategies are available to modulate
glutaminase activity, such as the use of organo-selenium compounds. All these factors
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may promote the formation of an organ specific (in this case bone metastatic) niche. As
described in the text, the balance of these processes may also help determine the extent
of tumor dormancy. Further studies are needed to examine all the hypotheses proposed.
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